Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Safety and efficacy of the fully human IL-12/-23 monoclonal antibody, ABT-874, in the treatment of moderate to severe plaque psoriasis: Results from a Phase II trial

Kimball AB, Gordon KB, Valdes JM. . Safety and efficacy of the fully human IL-12/-23 monoclonal antibody, ABT-874, in the treatment of moderate to severe plaque psoriasis: Results from a Phase II trial. Society for Investigative Dermatology, Annual Meeting, Los Angeles, California. 2007.


© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.